Skip to content
OpenCapital
Get started

Nektar Therapeutics NKTR Non Cash Interest Expense Related To Sale Of Royalties

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.19B+1,531%

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%—
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Nektar Therapeutics's non cash interest expense related to sale of royalties?
Nektar Therapeutics (NKTR) reported non cash interest expense related to sale of royalties of $7.94M in Q1 2026.
How has Nektar Therapeutics's non cash interest expense related to sale of royalties changed year-over-year?
Nektar Therapeutics's non cash interest expense related to sale of royalties increased by 59.7% year-over-year, from $4.97M to $7.94M.
What is the long-term trend for Nektar Therapeutics's non cash interest expense related to sale of royalties?
Over 4 years (2021 to 2025), Nektar Therapeutics's non cash interest expense related to sale of royalties has grown at a -13.7% compound annual growth rate (CAGR), from $47.31M to $26.18M.